Cara Leahy, DO
Neurology · Owosso, MINPI 1245438134
Payments from drug & device makers
Across 408 payments — averaging $524.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$86K
- Lilly USA, LLC$66K
- Eli Lilly$31K
- Biogen$15K
- C2n Diagnostics, LLC$14K
- AbbVie$452
- plus $2K from 32 others
Across 1 payment — averaging $2006.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Consulting fees$78,47343%
- Speaking & faculty fees$86,00147%
- Travel & lodging$13,6027%
- Food & beverage$6,3733%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 124 | $86,155 |
| Lilly USA, LLC | 116 | $65,721 |
| Eli Lilly | 21 | $30,579 |
| Biogen | 24 | $15,286 |
| C2n Diagnostics, LLC | 4 | $13,835 |
| AbbVie(2 entities) | 37 | $452 |
| Novartis | 15 | $300 |
| Life Molecular Imaging Ltd | 2 | $231 |
| UCB, Inc. | 8 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $120 |
| EMD Serono, Inc. | 1 | $107 |
| AstraZeneca(2 entities) | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $65 |
| Genentech USA, Inc. | 3 | $61 |
| Averitas Pharma Inc. | 3 | $56 |
| Acorda Therapeutics, Inc | 3 | $56 |
| Amgen | 3 | $50 |
| Tanabe Pharma America, Inc. | 2 | $48 |
| Amneal Pharmaceuticals LLC | 2 | $46 |
| Grifols USA, LLC | 2 | $45 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Pfizer | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Sanofi | 2 | $38 |
| GE HealthCare | 2 | $37 |
| Johnson & Johnson | 1 | $34 |
| Aucta Pharmaceuticals, Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| SK Life Science, Inc. | 1 | $24 |
| Catalyst Pharmaceuticals, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Kedrion Biopharma, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| CSL Behring | 1 | $14 |
| Corium, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$213,947 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 23 | $111,688 |
| RexultiBrexpiprazole | 25 | $67,534 |
| Memantine Hcl | 635 | $15,052 |
| RytaryCarbidopa/Levodopa | 16 | $8,771 |
| RivastigmineRivastigmine Tartrate | 137 | $6,905 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 100 | $6,678 |
| Donepezil Hcl | 495 | $6,562 |
| Rivastigmine | 43 | $5,524 |
| Levetiracetam | 62 | $2,833 |
| Quetiapine Fumarate | 190 | $2,129 |
| Rasagiline Mesylate | 17 | $2,070 |
| Trazodone Hcl | 194 | $2,056 |
| Memantine Hcl ErMemantine Hcl | 63 | $1,813 |
| Lacosamide | 39 | $1,496 |
| Olanzapine | 51 | $1,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $42 | $111,68823 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $15 | $67,53425 claims |
| Amneal Pharmaceuticals LLCRytary | $46 | $8,77116 claims |
| Lilly USA, LLCOlanzapine | $65,721 | $1,01851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.
Other neurology in Owosso
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
- Robert PaceOwosso$1M
- Rosemarie WalchOwosso$757K
- Margaret FreyOwosso$540K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.